My primary research interest involves the molecular pathways that play a role in the pathogenesis of B cell malignancies and their recurrences. These include transcriptional networks that control normal B cell development and maturation, as well as factors that mediate therapy resistance and drive clonal evolution towards relapsed disease. Furthermore, the identification of second primary malignancies may lead to discovery of novel genetic factors that predispose to lymphoid malignancies. Future research will also include studies on the interaction between malignant B cells with their immune microenvironment, which could play an important role in regulating differential immunotherapy responses.
> read more
Department of Pathology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands
Katerndahl CDS, Heltemes-Harris LM, Willette MJL, Henzler CM, Frietze S, Yang R, Schjerven H, Silverstein KAT, Ramsey LB, Hubbard G, Wells AD, Kuiper RP, Scheijen B, van Leeuwen FN, Muschen M, Kornblau SM, Farrar MA. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol 2017.
Scheijen B, Boer JM, Marke R, Tijchon E, van Ingen Schenau D, Waanders E, van Emst L, van der Meer LT, Pieters R, Escherich G, Horstmann MA, Sonneveld E, Venn N, Sutton R, Dalla-Pozza L, Kuiper RP, Hoogerbrugge PM, den Boer ML, van Leeuwen FN. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients. Haematologica 2017.
Waanders E, Scheijen B, Jongmans MCJ, Venselaar H, van Reijmersdal SV, van Dijk AHA, Pastorczak A, Weren RDA, van der Schoot CE, van de Vorst M, Sonneveld E, Hoogerbrugge N, van der Velden, VHJ, Gruhn B, Hoogerbrugge PM, van Dongen JJM, Geurts van Kessel A, van Leeuwen FN, Kuiper RP. Germline activating TYK2 mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences. Leukemia 2017.
Tijchon E, van Emst L, Yuniati L, van Ingen Schenau D, Havinga J, Rouault JP, Hoogerbrugge PM, van Leeuwen FN, Scheijen B. Tumor suppressors BTG1 and BTG2 regulate early mouse B-cell development. Haematologica 2016.
Marke R, Havinga J, Cloos J, Demkes M, Poelmans G, Yuniati L, van Ingen Schenau D, Sonneveld E, Waanders E, Pieters R, Kuiper RP, Hoogerbrugge PM, Kaspers GJ, van Leeuwen FN, Scheijen B. Tumor suppressor IKZF1 mediates glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. Leukemia 2016.
Esther Tijchon: BTG proteins, novel regulators of B-cell development and leukemogenesis. Awarded: 2016
Current PhD projects
Rene Marke: Role of IKZF1 in therapy resistance of B cell precursor acute lymphoblastic leukemia
Diede van Bladel: Clonal relationship and mutational analysis of Hodgkin lymphoma recurrences
Madeleine Berendsen: Clonal evolution and genomic landscape of primary and relapsed diffuse large B cell lymphoma